Xenetic Biosciences Balance Sheet - Quarterly (NASDAQ:XBIO)

Add to My Stocks
$2.58 $0.07 (2.79%) XBIO stock closing price Sep 17, 2018 (Closing)

The financial analysis of a company like Xenetic Biosciences involves checking the three financial statements of the company in detail, of which the balance sheet is one. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Xenetic Biosciences stock analysis, and provides insights into the firm's financial performance. A company releases its balance sheet every quarter along with its quarterly results. The balance sheet shows total liabilities of $4.47M and shareholders equity of $12.78M. Xenetic Biosciences revenue and Xenetic Biosciences operating cash flow are important in understanding the financial capacity of the company.

View and download Xenetic Biosciences quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Marketable Securities----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets---1.24M1.43M1.82M1.22M--3.98M
Total Current Assets
Property Plant & Equipment----------
Accumulated Depreciation----------
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable---1.02M1.01M1.36M1M2.17M2.02M1.62M
Current Portion Long-Term Debt-------1.13M-7M
Current Portion Capital Leases----------
Accrued Expenses--1.15M1.13M---1.5M1.62M1.55M
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income2.92M2.91M2.91M2.91M2.91M2.91M2.91M2.91M2.91M2.91M
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus167.58M165.65M165.24M164.94M164.64M164.12M163.52M152.91M150.9M101.62M
Retained Earnings-149.78M-147.75M-145.93M-150.37M-148.12M-145.2M-142.33M-141.94M-139.47M-91.7M
Treasury Stock5.28M5.28M5.28M5.28M5.28M5.28M5.28M5.28M5.28M5.28M
Other Liabilities----------
Shareholders Equity12.78M12.88M14.3M9.55M11.5M13.9M16.16M5.95M6.41M5.06M
Total Liabilities & Shareholders Equity17.26M17.54M19.16M14.63M16.43M18.83M20.97M13.86M13.16M18.36M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our PHI Inc financial analysis

Most investors just check the Xenetic Biosciences stock price, and Xenetic Biosciences historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Xenetic Biosciences PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: XBIO total assets, which was at $17.26M for 2018 Q2 is a balance sheet item representing value of what Xenetic Biosciences owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Xenetic Biosciences is $4.47M. Shareholders equity comes under liabilities as it is money the company owes the holders of XBIO stock.

Xenetic Biosciences Balance Sheet - Key Ratios